The Effect of Atorvastatin on Oncogenic miRNAs in Hematological Malignancies: A Central Study
Open Access
- 7 December 2024
- journal article
- research article
- Published by MDPI AG in Biomolecules
- Vol. 14 (12) , 1559
Abstract
The efficacy of statins as anti-cancer drugs has been demonstrated in several malignancies but has been poorly investigated in hematological malignancies (HM). By studying its effect on oncogenic miRNAs, we investigated the effect of statin therapy on HM patients. The data were used to identify enriched pathways that were altered due to statin treatment. The main aim of this study was to identify significantly differentially expressed miRNAs and involved regulatory pathways post-atorvastatin treatment in HM patients. A panel of 95 plasma circulating miRNAs involved in tumorigenesis, apoptosis, and differentiation were relatively quantified using qPCR for blood samples obtained from 12 HM patients, 4 with Chronic Myeloid Leukemia (CML), 4 with Non-Hodgkin Lymphoma (NHL), and 4 with Essential Thrombocythemia. Pre- and post-administration of a 6-week atorvastatin course miRNA expression levels were measured. Significantly differentially expressed miRNAs were those with a fold change >2 or p-value < 0.05. To further understand the underlying mechanism of statin regulated miRNA, GO and KEGG pathway enrichment analyses were conducted for identified target genes using the DAVID 6.8 bioinformatics tool. Out of 95 miRNAs, 14 exhibited significant fold changes post-treatment with statins including miR-198, miR-29a+b+c, miR-204, miR-222, miR-224, miR-155, miR-128b, miR-296, miR-199a+b, miR-194, miR-125a, miR-200a, and the let-7-family that were upregulated and miR-150 that was downregulated post-statin treatment. Higher mir-222, mir-194, mir-128b, and mir-199b expressions were significantly associated with better overall survival using the Cancer Genomic Atlas leukemia and lymphoma patient cohorts. Enrichment analysis identified the PI3k-Akt pathway as well as other pathways involved in the epithelial–mesenchymal transition. Atorvastatin upregulated several tumor suppressor genes involved in mediating better prognosis. The data can be used to enhance personalized treatments for patients with hematological malignancies by helping to predict the different pathways that may be targeted and, therefore, result in better survival outcomes in these patients.Keywords
Funding Information
- Jordan University of Science and Technology (20190255)
This publication has 60 references indexed in Scilit:
- The dual regulatory role of miR-204 in cancerTumor Biology, 2016
- Statins use and the risk of all and subtype hematological malignancies: a meta‐analysis of observational studiesCancer Medicine, 2015
- Drug resistance-related microRNAs in hematological malignancies: Translating basic evidence into therapeutic strategiesBlood Reviews, 2015
- HMG-CoA reductase inhibitors as adjuvant treatment for hematologic malignancies: what is the current evidence?Annals of Hematology, 2014
- Overcoming obstacles in microRNA delivery towards improved cancer therapyDrug Delivery and Translational Research, 2013
- Impact of miR-155 and miR-126 as novel biomarkers on the assessment of disease progression and prognosis in adult T-cell leukemiaCancer Epidemiology, 2012
- Targeted therapy in haematological malignanciesThe Journal of Pathology, 2009
- Allogeneic hematopoietic stem cell transplantation for adult acute lymphocytic leukemiaCurrent Hematologic Malignancy Reports, 2009
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- Treatment of hematological malignancies relapsing after allogeneic bone marrow transplantationBlood Reviews, 1994